Sutro Biopharma (STRO) Retained Earnings (2017 - 2025)

Sutro Biopharma has disclosed Retained Earnings across 9 years of filings, most recently posting -$978.0 million for Q4 2025.

• Retained Earnings for Q4 2025 came in at -$978.0 million, down 24.28% year-over-year; the trailing twelve-month figure through Dec 2025 was -$978.0 million (down 24.28% YoY), and the FY2025 annual result was -$978.0 million, down 24.28% from the prior year.
• Retained Earnings came in at -$978.0 million for Q4 2025 at Sutro Biopharma, down from -$931.2 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $106000.0 in Q3 2024 to a low of -$978.0 million in Q4 2025.
• The 5-year median for Retained Earnings is -$276.8 million (2021), against an average of -$339.6 million.
• Peak annual rise in Retained Earnings reached 1414.29% in 2024, while the deepest fall reached 3747095.24% in 2024.
• Sutro Biopharma's Retained Earnings stood at -$333.4 million in 2021, then tumbled by 35.75% to -$452.6 million in 2022, then soared by 100.0% to $21000.0 in 2023, then slumped by 3747095.24% to -$786.9 million in 2024, then retreated by 24.28% to -$978.0 million in 2025.
• The last three Retained Earnings figures came in at -$978.0 million (Q4 2025), -$931.2 million (Q3 2025), and -$874.3 million (Q2 2025), per Business Quant data.